Large‐scale clinical cohort studies are needed to assess its prognostic value across glioma subtypes, and mechanistic investigations should explore APOBEC3C's involvement in immune evasion, ultimately paving the way for clinical translation of APOBEC3C‐targeted therapies to enhance immunotherapy outcomes. Here, APOBEC3C is linked to central nervous system cancer.